Thrivent Financial for Lutherans reduced its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 0.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,063,175 shares of the medical research company’s stock after selling 6,426 shares during the quarter. Thrivent Financial for Lutherans owned about 0.33% of Edwards Lifesciences worth $164,682,000 at the end of the most recent reporting period.
Other institutional investors also recently bought and sold shares of the company. Exchange Traded Concepts LLC grew its position in shares of Edwards Lifesciences by 66.1% during the 3rd quarter. Exchange Traded Concepts LLC now owns 8,202 shares of the medical research company’s stock worth $655,000 after buying an additional 3,263 shares during the period. Smithfield Trust Co. grew its position in shares of Edwards Lifesciences by 410.1% during the 2nd quarter. Smithfield Trust Co. now owns 1,413 shares of the medical research company’s stock worth $98,000 after buying an additional 1,136 shares during the period. Tocqueville Asset Management L.P. grew its position in shares of Edwards Lifesciences by 195.5% during the 2nd quarter. Tocqueville Asset Management L.P. now owns 111,390 shares of the medical research company’s stock worth $7,698,000 after buying an additional 73,690 shares during the period. Kentucky Retirement Systems acquired a new position in shares of Edwards Lifesciences during the 2nd quarter worth about $2,384,000. Finally, Atom Investors LP lifted its holdings in shares of Edwards Lifesciences by 55.3% during the 2nd quarter. Atom Investors LP now owns 4,369 shares of the medical research company’s stock valued at $302,000 after purchasing an additional 1,556 shares in the last quarter. Institutional investors own 79.70% of the company’s stock.
Shares of EW stock traded down $0.71 during trading on Friday, reaching $84.53. 2,794,802 shares of the company’s stock were exchanged, compared to its average volume of 3,594,272. The company has a quick ratio of 2.61, a current ratio of 3.52 and a debt-to-equity ratio of 0.14. The stock has a market capitalization of $52.68 billion, a PE ratio of 67.62, a PEG ratio of 2.48 and a beta of 0.92. Edwards Lifesciences Co. has a twelve month low of $51.51 and a twelve month high of $88.00. The firm’s fifty day moving average price is $80.32 and its 200-day moving average price is $86.20.
In other Edwards Lifesciences news, CEO Michael A. Mussallem sold 68,550 shares of the company’s stock in a transaction on Tuesday, September 29th. The stock was sold at an average price of $78.74, for a total value of $5,397,627.00. Following the transaction, the chief executive officer now directly owns 309,770 shares of the company’s stock, valued at approximately $24,391,289.80. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Larry L. Wood sold 10,698 shares of the company’s stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $85.09, for a total value of $910,292.82. Following the completion of the transaction, the vice president now directly owns 374,181 shares in the company, valued at $31,839,061.29. The disclosure for this sale can be found here. Insiders have sold a total of 444,244 shares of company stock worth $36,078,923 over the last three months. 1.48% of the stock is owned by insiders.
Several equities analysts have recently weighed in on the company. Wells Fargo & Company lifted their price objective on Edwards Lifesciences from $84.00 to $87.00 and gave the company an “equal weight” rating in a report on Wednesday. Cowen lifted their price objective on Edwards Lifesciences from $85.00 to $100.00 and gave the company an “outperform” rating in a report on Monday, October 19th. SVB Leerink lifted their price objective on Edwards Lifesciences from $95.00 to $100.00 and gave the company an “outperform” rating in a report on Monday, October 12th. Wolfe Research began coverage on Edwards Lifesciences in a report on Friday, September 11th. They set an “underperform” rating on the stock. Finally, Piper Sandler boosted their target price on Edwards Lifesciences from $91.00 to $93.00 and gave the company an “overweight” rating in a research note on Wednesday, October 14th. Two analysts have rated the stock with a sell rating, five have issued a hold rating and fourteen have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $87.16.
Edwards Lifesciences Company Profile
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.
See Also: Terms to Better Understand Call Options
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EW).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.